TY - CHAP PY - 2006 DA - 2006// BT - Cancer Facts & Figures 2006 PB - American Cancer Society CY - Atlanta, GA ID - ref1 ER - TY - JOUR AU - Motzer, R. J. AU - Russo, P. PY - 2000 DA - 2000// TI - Systemic therapy for renal cell carcinoma JO - J Urol VL - 163 UR - https://doi.org/10.1016/S0022-5347(05)67889-5 DO - 10.1016/S0022-5347(05)67889-5 ID - Motzer2000 ER - TY - JOUR AU - Borden, E. C. AU - Parkinson, D. PY - 1998 DA - 1998// TI - A perspective on the clinical effectiveness and tolerance of interferon-alpha JO - Semin Oncol VL - 25 ID - Borden1998 ER - TY - JOUR AU - Yang, J. C. AU - Haworth, L. AU - Sherry, R. M. AU - Hwu, P. AU - Schwartzentruber, D. J. AU - Topalian, S. L. AU - Steinberg, S. M. AU - Chen, S. X. AU - Rosenberg, S. A. PY - 2003 DA - 2003// TI - A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer JO - N Engl J Med VL - 349 UR - https://doi.org/10.1056/NEJMoa021491 DO - 10.1056/NEJMoa021491 ID - Yang2003 ER - TY - CHAP AU - Ratain, M. J. AU - Flaherty, K. T. AU - Stadler, W. M. AU - O'Dwyer, P. AU - Kaye, S. AU - Xiong, H. AU - Patnaik, A. AU - Gore, M. AU - Lee, R. J. AU - Eisen, T. PY - 2004 DA - 2004// BT - Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT) [abstract 4501]: ; New Orleans, LA. ID - Ratain2004 ER - TY - JOUR AU - Stadler, W. M. PY - 2005 DA - 2005// TI - Targeted agents for the treatment of advanced renal cell carcinoma JO - Cancer VL - 104 UR - https://doi.org/10.1002/cncr.21453 DO - 10.1002/cncr.21453 ID - Stadler2005 ER - TY - JOUR AU - Motzer, R. J. AU - Michaelson, M. D. AU - Redman, B. G. AU - Hudes, G. R. AU - Wilding, G. AU - Figlin, R. A. AU - Ginsberg, M. S. AU - Kim, S. T. AU - Baum, C. M. AU - DePrimo, S. E. AU - Li, J. Z. AU - Bello, C. L. AU - Theuer, C. P. AU - George, D. J. AU - Rini, B. I. PY - 2006 DA - 2006// TI - Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.02.2574 DO - 10.1200/JCO.2005.02.2574 ID - Motzer2006 ER - TY - JOUR AU - Bacik, J. AU - Mazumdar, M. AU - Fairclough, D. L. AU - Murphy, B. A. AU - Mariani, T. AU - Motzer, R. J. AU - Cella, D. PY - 2004 DA - 2004// TI - The Functional Assessment of Cancer Therapy-BRM (FACT-BRM): A new tool for the assessment of quality of life in patients treated with biologic response modifiers JO - Qual Life Res VL - 13 UR - https://doi.org/10.1023/B:QURE.0000015297.91158.01 DO - 10.1023/B:QURE.0000015297.91158.01 ID - Bacik2004 ER - TY - JOUR AU - Motzer, R. J. AU - Murphy, B. A. AU - Bacik, J. AU - Schwartz, L. H. AU - Nanus, D. M. AU - Mariani, T. AU - Loehrer, P. AU - Wilding, G. AU - Fairclough, D. L. AU - Cella, D. AU - Mazumdar, M. PY - 2000 DA - 2000// TI - Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma JO - J Clin Oncol VL - 18 ID - Motzer2000 ER - TY - JOUR AU - Yost, K. J. AU - Eton, D. T. PY - 2005 DA - 2005// TI - Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience JO - Evaluation & the Health Professions VL - 28 UR - https://doi.org/10.1177/0163278705275340 DO - 10.1177/0163278705275340 ID - Yost2005 ER - TY - JOUR AU - Motzer, R. J. AU - Mazumdar, M. AU - Bacik, J. AU - Berg, W. AU - Amsterdam, A. AU - Ferrara, J. PY - 1999 DA - 1999// TI - Survival and prognostic significance of 670 patients with advanced renal cell carcinoma JO - J Clin Oncol VL - 17 ID - Motzer1999 ER - TY - CHAP AU - Cohen, J. PY - 1988 DA - 1988// BT - Statistical Power Analysis for the Behavioral Sciences PB - Erlbaum CY - Hillsdale, NJ ID - Cohen1988 ER - TY - CHAP PY - 2006 DA - 2006// BT - Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims PB - US Food and Drug Administration CY - Rockville, MD ID - ref13 ER - TY - STD TI - Eton DT, Yost KJ, Cella D: Future trends in patient-reported outcomes assessment for patients with advanced-stage lung cancer receiving targeted therapy.Clin Lung Cancer, in press. ID - ref14 ER - TY - JOUR AU - Rini, B. I. AU - Sosman, J. A. AU - Motzer, R. J. PY - 2005 DA - 2005// TI - Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: Biology, clinical results and future development JO - BJU Int VL - 96 UR - https://doi.org/10.1111/j.1464-410X.2005.05616.x DO - 10.1111/j.1464-410X.2005.05616.x ID - Rini2005 ER -